Prostate Cancer Screening and Follow-Up Guidelines

Risk Stratification Based on PSA Level

Men with PSA <1.0 ng/mL at age 57 have an extremely low risk of metastatic prostate cancer or prostate cancer death over the next 25 years 1, 2
The median PSA for men aged 40-49 years ranges from 0.5-0.7 ng/mL, with 75th percentile values of 0.7-0.9 ng/mL, placing this patient at the upper range of normal but still within acceptable limits 3

Free PSA percentage is primarily useful for risk stratification when total PSA is in the 4-10 ng/mL range 4
At a total PSA of 0.9 ng/mL, the diagnostic usefulness of free PSA percentage has not been established, and this value should not influence management decisions 3

Repeat PSA testing should occur at 2-4 year intervals, with no digital rectal examination required at this PSA level unless clinically indicated by symptoms 1, 4
If PSA remains <1.0 ng/mL at subsequent testing, continue 2-4 year intervals 1
If PSA rises to ≥1.0 ng/mL but <3.0 ng/mL, shorten interval to 1-2 years 1, 3
If PSA rises to >3.0 ng/mL, perform repeat PSA in 6-12 months and consider additional workup including DRE and potentially free PSA percentage or other biomarkers 1

A single elevated PSA should never prompt immediate biopsy and must be verified by a second measurement 5
The probability of prostate cancer at PSA 0-2.5 ng/mL is approximately 1%, making aggressive surveillance or intervention inappropriate at this time 4